Drug Screening Systems Market | Size, Growth Forecast, Market Share

Market Summary and Growth Forecast

The global Drug Screening Systems Market is valued at $6,480 million in 2026 and is expected to appreciate to $10,950 million by 2035, at a CAGR of 6.0%.

Drug screening systems comprise instruments, analytical platforms, consumables, software, and integrated workflows used to identify, measure, confirm, or characterize drugs, drug candidates, metabolites, and related compounds. Their use spans pharmaceutical research, clinical testing, toxicology, forensic laboratories, workplace screening, sports testing, and regulatory or public-sector applications.

In 2026, the market is moving beyond the traditional model of laboratory-based testing toward more connected screening environments. Laboratories increasingly want higher throughput, lower manual intervention, better analytical sensitivity, and faster interpretation of complex results. This shift is supporting demand for automated screening platforms, chromatography- and mass-spectrometry-based workflows, immunoassay systems, and software that helps laboratories manage large testing volumes.

The growth outlook through 2035 is supported by several structural forces. Pharmaceutical R&D remains a major source of demand because early-stage drug discovery requires repeated screening of large compound libraries. At the same time, clinical and forensic laboratories are dealing with increasingly complex drug mixtures, synthetic compounds, prescription-drug misuse, and new psychoactive substances. These conditions raise the value of systems that can distinguish closely related compounds rather than simply produce a positive or negative result.

Regulatory expectations are another important factor. Laboratories handling clinical, forensic, and pharmaceutical testing need validated procedures, traceable results, quality controls, and reproducible analytical performance. This favors established platforms with strong documentation and dependable workflows. It also raises the importance of software integration, audit trails, automated quality checks, and standardized data handling.

Technology is changing the economics of screening as well. High-resolution analytical instruments can examine broader compound profiles, while automation allows laboratories to process more samples without increasing staffing at the same rate. The benefit is not limited to speed. Better analytical coverage can reduce the risk of missing compounds that would be difficult to detect through simpler screening methods.

Market Indicator	2026 Estimate	2035 Forecast	2026–2035 Outlook
Global Market Size	$6.48 billion	$10.95 billion	6.0% CAGR
Pharmaceutical & biotechnology testing demand	High	Very High	Expanding
Clinical and toxicology screening	High	Very High	Expanding
Forensic and public-sector testing	Moderate–High	High	Steady expansion
Workplace and other screening	Moderate	Moderate–High	Selective growth
Automation/software integration	Emerging–High	High	Rapid adoption

The principal consumers include pharmaceutical companies, biotechnology firms, contract research organizations, hospitals, diagnostic laboratories, forensic agencies, government testing laboratories, academic research centers, and organizations conducting workplace or compliance testing.

Pharmaceutical and biotechnology customers tend to prioritize screening capacity, analytical depth, and integration with research workflows. Clinical and forensic users place greater emphasis on accuracy, confirmation capability, turnaround time, and regulatory compliance. This creates a diverse demand base rather than a single purchasing model.

From a business perspective, the Drug Screening Systems Market should remain relatively resilient because testing is embedded in several essential workflows. Drug development cannot easily scale without screening, while clinical and forensic testing continues to require dependable analytical infrastructure. The larger opportunity through 2035 will likely come from replacing fragmented laboratory processes with connected, automated systems.

Expert view: “The next phase of competition will be less about selling an individual instrument and more about improving the complete screening workflow—from sample preparation and detection through interpretation, documentation, and reporting.”

The projected $10.95 billion market size by 2035 therefore reflects a combination of rising testing volumes, technology replacement, higher analytical requirements, and greater laboratory automation rather than dependence on one demand driver.

Market Segmentation and Forecast Scope

The Drug Screening Systems Market can be assessed across four principal dimensions: Product Type, Application, End User, and Region. Each dimension captures a different part of the purchasing decision and helps identify where future spending is likely to concentrate.

By Product Type

The market includes analytical instruments, screening assays and test systems, sample preparation equipment, consumables, and associated software or data-management solutions.

Analytical instruments form the technology-intensive portion of the market. Chromatography-based systems, mass spectrometry platforms, immunoassay systems, and other analytical technologies serve different levels of screening complexity. Instruments capable of confirmatory analysis generally command higher value because they can provide deeper compound identification.

Consumables represent a recurring revenue stream. These include assay components, columns, reagents, cartridges, plates, and other materials required to maintain routine testing. Software is becoming more strategically important as laboratories connect instruments and manage larger data volumes.

Within this dimension, analytical instruments are estimated to account for approximately 42% of global revenue in 2026, making them the largest disclosed product category. Screening assays and test systems represent another important segment, particularly where rapid or high-volume testing is required.

The fastest strategic opportunity is increasingly concentrated in integrated and automated screening platforms. Customers are showing greater interest in systems that reduce manual sample handling and connect multiple stages of the testing process.

By Application

Application areas include pharmaceutical and drug discovery screening, clinical toxicology, forensic testing, workplace drug testing, sports testing, and other specialized uses.

Pharmaceutical and drug discovery applications benefit from the continuing need to evaluate candidate compounds and understand their biological and chemical behavior. Screening requirements can range from early compound identification to more advanced analytical characterization.

Clinical toxicology is driven by the need to identify drugs and metabolites in patient samples, particularly in emergency, pain-management, addiction-treatment, and therapeutic-monitoring environments.

Forensic testing has a different operating model. Laboratories may need to identify compounds in highly complex samples and produce results that can withstand legal scrutiny. This makes confirmatory analytical capability especially important.

Workplace and sports testing tend to place greater emphasis on throughput, standardized protocols, and rapid processing. Their purchasing priorities can therefore differ from those of research laboratories.

By End User

The principal end users include pharmaceutical and biotechnology companies, hospitals and clinical laboratories, forensic laboratories, contract research organizations, government agencies, academic institutions, and workplace testing providers.

Pharmaceutical and biotechnology companies remain a high-value customer group because screening is integrated into the broader drug-development process. Contract research organizations are also important because they serve multiple pharmaceutical clients and often need flexible, scalable laboratory capacity.

Hospitals and diagnostic laboratories focus more heavily on turnaround time, reliability, operational simplicity, and compliance. Forensic and government laboratories place additional weight on validation, traceability, and defensible analytical results.

A notable strategic shift is the movement toward centralized, high-throughput laboratories. Consolidation can increase sample volumes at individual facilities, creating a stronger business case for automation and advanced analytical platforms.

By Region

The regional scope covers North America, Europe, Asia Pacific, and LAMEA.

North America remains a major revenue center because of its mature pharmaceutical industry, established laboratory infrastructure, large clinical testing base, and strong adoption of advanced analytical technologies.

Europe benefits from sophisticated pharmaceutical and biotechnology activity, established regulatory systems, and demand for standardized laboratory testing. Replacement demand and technology upgrades are important contributors.

Asia Pacific represents the most strategic expansion region. Pharmaceutical manufacturing, clinical research, biotechnology investment, and laboratory modernization are increasing across several major economies. Demand is also being supported by the gradual development of more sophisticated testing infrastructure.

LAMEA remains a smaller portion of global revenue but offers targeted opportunities. Adoption is strongest where pharmaceutical manufacturing, clinical laboratory capacity, forensic infrastructure, or government testing programs are expanding.

Segmentation Dimension	Major Segments	Strategic Assessment
Product Type	Instruments, assays/test systems, consumables, software	Automation and integrated systems gaining importance
Application	Drug discovery, clinical toxicology, forensic, workplace, sports	High-value demand concentrated in research and confirmatory testing
End User	Pharma/biotech, hospitals, CROs, forensic labs, government, academia	Pharma and centralized laboratories remain important buyers
Region	North America, Europe, Asia Pacific, LAMEA	Asia Pacific offers strongest expansion potential

The segmentation outlook shows that future market value will not be distributed evenly. Advanced analytical platforms should capture a larger share of spending as laboratories demand better compound coverage and more reliable confirmation. At the same time, recurring consumables and software can provide vendors with revenue streams that extend beyond the initial instrument sale.

Expert view: “Asia Pacific is likely to become increasingly important not simply because of sample volumes, but because laboratories in the region are moving toward the same automation and analytical standards already established in mature markets.”

For suppliers, this makes segmentation strategy critical. A product designed for pharmaceutical discovery will compete on different criteria from a system intended for high-volume clinical or forensic screening. Understanding that distinction can influence pricing, distribution, service models, and product development.

Market Trends and Business Innovations

Innovation in the Drug Screening Systems Market is increasingly focused on making screening faster, more selective, and easier to manage at scale. The direction of R&D is shifting from isolated improvements in detection toward improvements across the entire laboratory workflow.

Automation Is Moving From Individual Steps to Complete Workflows

Laboratories have traditionally automated specific activities such as liquid handling, sample preparation, or instrument injection. The newer direction is broader workflow integration.

Automated sample preparation can reduce repetitive manual work and improve consistency between batches. When combined with automated analytical runs and laboratory information systems, it creates a more continuous testing process.

This is particularly valuable for high-volume laboratories. A system that saves only a few minutes per sample can produce substantial operational benefits when thousands of samples are processed each month.

Expert view: “Automation will create the greatest value where sample volume is high and staffing is difficult to scale. The commercial advantage comes from reducing bottlenecks, not simply adding robotics.”

Higher Analytical Resolution Is Changing Screening Strategies

Another important trend is the increased use of analytical platforms capable of detecting a broader range of compounds and metabolites.

Traditional screening approaches remain useful for routine testing, especially where speed and cost are the primary considerations. However, complex samples can require more detailed analysis. High-resolution analytical technologies allow laboratories to investigate compounds beyond a predefined narrow target list.

This is becoming particularly relevant as laboratories encounter changing drug formulations, emerging synthetic compounds, and mixtures that are difficult to characterize using basic screening alone.

AI and Data Analytics Are Entering the Workflow

Artificial intelligence is relevant to this market, but its role should be viewed realistically. AI is not replacing the analytical measurement itself. Instead, it is being applied to areas such as pattern recognition, data interpretation, anomaly identification, compound matching, and workflow prioritization.

Large analytical datasets can be difficult for laboratory personnel to review manually. Software-assisted interpretation can help identify unusual signals or relationships that deserve additional investigation.

The commercial opportunity is therefore likely to develop around AI-assisted interpretation, rather than fully autonomous drug identification.

Expert view: “AI should be treated as an interpretation layer around validated analytical data. Its value will depend on accuracy, traceability, and the laboratory’s ability to review and document the result.”

Software Integration Is Becoming a Buying Criterion

Instrument performance is no longer the only consideration during procurement. Laboratories increasingly evaluate how easily systems communicate with existing laboratory information systems, electronic records, and data-management environments.

Better connectivity can reduce duplicate data entry and improve traceability. It can also make it easier for laboratory managers to monitor throughput, instrument utilization, quality-control performance, and turnaround time.

This creates an opening for vendors to compete through software and service capabilities rather than relying solely on hardware specifications.

Partnerships Are Expanding Around the Laboratory Ecosystem

The competitive environment is also encouraging partnerships between instrument manufacturers, laboratory software providers, diagnostic organizations, pharmaceutical companies, and research institutions.

These relationships can help vendors validate workflows in real laboratory environments and shorten the path from technology development to commercial adoption. Collaboration is particularly useful for complex screening applications where instrument performance alone does not determine the value of the solution.

R&D Is Becoming More Application-Specific

A broad instrument platform may serve several markets, but customers increasingly want application-ready workflows. Vendors are therefore investing in validated methods, standardized sample preparation, application libraries, automated reporting, and workflow-specific software.

This trend may change how products are marketed. Instead of presenting an instrument as a standalone laboratory asset, suppliers can position the system as a complete solution for a particular testing requirement.

Business Model Innovation

Recurring revenue is becoming more attractive as equipment markets mature. Consumables, software subscriptions, maintenance agreements, workflow services, and application support can create longer customer relationships.

For buyers, this can reduce the complexity of managing multiple suppliers. For vendors, it can provide a more predictable revenue base.

Innovation Area	Current Direction	Likely Business Impact Through 2035
Automation	Automated preparation and integrated workflows	Higher throughput and lower manual workload
Analytical technology	Greater sensitivity and broader compound coverage	Stronger confirmatory testing capability
AI/data analytics	Assisted interpretation and anomaly detection	Faster review of complex datasets
Connectivity	Instrument-to-LIMS and data integration	Better traceability and workflow control
Application development	Ready-to-use validated workflows	Easier adoption and stronger customer retention
Commercial models	Service, software, and consumable-linked revenue	Greater recurring revenue potential

Overall, innovation is pushing the Drug Screening Systems Market toward an integrated laboratory model. Hardware remains central, but the competitive difference is increasingly created by workflow efficiency, data interpretation, software connectivity, application support, and service.

Expert view: “By the early 2030s, the strongest platforms are likely to compete as connected screening ecosystems. Instrument specifications will still matter, but ease of integration and the ability to turn raw analytical data into defensible decisions may matter more.”

The implication for suppliers is clear: R&D budgets need to cover not only detection performance but also automation, software, workflow validation, and customer support. For laboratories, the key purchasing question will increasingly shift from “How sensitive is the instrument?” to “How much of our screening process can this system improve?”

Competitive Intelligence and Benchmarking

The competitive structure of the Drug Screening Systems Market is led by companies with broad analytical portfolios, established laboratory relationships, strong application expertise, and global service networks. Competition is not limited to instrument specifications. Buyers also evaluate automation, analytical sensitivity, workflow integration, software, consumables, validation support, and after-sales service.

Thermo Fisher Scientific

Thermo Fisher Scientific maintains a broad position across analytical instruments, sample preparation, laboratory software, and mass-spectrometry-based workflows. Its portfolio allows it to serve pharmaceutical research, clinical toxicology, forensic analysis, and high-throughput laboratory environments.

Its main advantage is the ability to combine multiple laboratory requirements within one supplier ecosystem. This is valuable for large institutional customers seeking standardized workflows and integrated support.

Thermo Fisher is particularly well positioned where laboratories want to consolidate several stages of drug screening under a coordinated technology platform.

Agilent Technologies

Agilent Technologies has a strong presence in chromatography, mass spectrometry, sample preparation, and laboratory workflow solutions. Its technologies are widely suited to pharmaceutical laboratories, toxicology facilities, research organizations, and forensic testing centers.

The company benefits from an established installed base and deep application expertise. Its systems can support routine targeted screening as well as more advanced confirmatory analysis.

Agilent’s future opportunity is closely linked to combining analytical performance with automation and improved data management.

Waters Corporation

Waters Corporation competes strongly in liquid chromatography, mass spectrometry, informatics, and analytical workflow management.

Its position is particularly strong within pharmaceutical and biotechnology laboratories, where analytical testing is closely integrated with drug discovery, development, and quality processes.

The combination of analytical equipment and informatics gives the company an advantage in laboratories that want standardized workflows and integrated data handling. Once such systems become embedded into laboratory processes, customer switching can become more difficult.

Shimadzu Corporation

Shimadzu Corporation offers a diversified analytical portfolio covering chromatography, mass spectrometry, spectroscopy, and related laboratory systems.

Its international presence and strong position across Asian markets provide an important competitive advantage. The company can serve both sophisticated research laboratories and facilities looking for reliable analytical platforms with manageable operating requirements.

Growing pharmaceutical and biotechnology activity across Asia should create additional opportunities for its analytical systems.

SCIEX

SCIEX is strongly associated with mass-spectrometry-based analytical workflows for pharmaceutical, clinical, and forensic applications.

Its competitive strength lies in quantitative and targeted analysis where sensitivity, selectivity, and reproducibility are critical. These capabilities are particularly relevant for toxicology laboratories dealing with complex biological samples and low-concentration compounds.

The expansion of broader drug panels and more automated workflows should support continued demand for advanced mass-spectrometry solutions.

Bio-Rad Laboratories

Bio-Rad Laboratories has a diversified laboratory portfolio spanning life-science research, clinical diagnostics, quality-control applications, and related testing environments.

Its exposure to the drug-screening ecosystem is broader than that of a specialist analytical-instrument supplier. The company can participate in laboratories where standardized testing, workflow efficiency, and laboratory automation are important.

Its diversified customer base provides resilience across different testing applications.

Danaher

Danaher has a broad presence across life sciences, diagnostics, laboratory technologies, and related healthcare applications through its operating companies.

Its competitive strength comes from diversification rather than reliance on one analytical technology. This gives the group exposure to pharmaceutical, biotechnology, clinical, research, and laboratory infrastructure spending.

The company’s broad ecosystem can support long-term opportunities as laboratories move toward connected analytical workflows.

Company	Core Competitive Strength	Primary Customer Exposure	Strategic Position
Thermo Fisher Scientific	Analytical instruments, MS, workflow integration	Pharma, clinical, forensic	Broad laboratory ecosystem
Agilent Technologies	Chromatography, MS, laboratory workflow	Pharma, toxicology, forensic	Strong analytical platform
Waters Corporation	LC, MS, informatics	Pharma, biotech, research	High-value analytical workflows
Shimadzu Corporation	Chromatography and analytical systems	Pharma, research, clinical	Strong Asian presence
SCIEX	Mass spectrometry and quantitative analysis	Clinical, forensic, pharma	High-sensitivity applications
Bio-Rad Laboratories	Laboratory and diagnostic technologies	Clinical, research	Diversified laboratory exposure
Danaher	Life-science and diagnostic ecosystem	Pharma, clinical, research	Diversified strategic exposure

Competition is increasingly moving toward platform-based selling. Vendors that can connect instruments, sample preparation, software, consumables, and technical support have an advantage over companies offering isolated equipment.

Expert view: “The strongest competitive positions will increasingly come from reducing manual handoffs while preserving analytical confidence, regulatory traceability, and ease of use.”

Regional Landscape and Adoption Outlook

Regional demand for the Drug Screening Systems Market differs substantially because pharmaceutical activity, healthcare infrastructure, laboratory investment, regulatory requirements, and forensic capabilities vary across countries.

United States

The United States remains one of the most mature markets for advanced drug-screening technologies.

Its large pharmaceutical and biotechnology sector creates demand throughout the drug-development cycle. Clinical toxicology and forensic laboratories add another important source of demand.

The country has a substantial installed base of advanced chromatography and mass-spectrometry systems. As these systems age, replacement and technology-upgrade cycles should provide continuing revenue opportunities.

Laboratories are also increasingly focused on throughput and workflow automation. This favors systems that can reduce manual preparation, improve analytical consistency, and simplify data interpretation.

Adoption outlook: Very high. Growth should be driven mainly by technology replacement, advanced testing requirements, automation, and higher analytical complexity.

Europe

Europe has a mature pharmaceutical, biotechnology, clinical, and forensic testing ecosystem.

Germany, the United Kingdom, France, Switzerland, and Italy represent important markets because of their pharmaceutical industries, research institutions, laboratory infrastructure, and established testing networks.

Regulatory requirements support demand for validated and traceable testing procedures. Laboratories also face increasing pressure to manage emerging substances and broader compound panels.

Growth is therefore likely to be steady rather than exceptionally rapid. Replacement of older equipment and upgrades toward more automated systems will remain important.

Adoption outlook: High. Growth should remain supported by pharmaceutical research, laboratory modernization, regulation, and replacement demand.

China

China represents one of the strongest long-term expansion opportunities.

Its large pharmaceutical manufacturing base, expanding biotechnology sector, academic research infrastructure, and growing laboratory capabilities create a broad potential customer base.

High sample volumes also make automation economically attractive. Large pharmaceutical companies and research organizations can gain measurable productivity benefits from integrated analytical systems.

Local technical support, application expertise, training, and competitive operating costs will remain important factors in winning customers.

Adoption outlook: High and expanding. China should remain one of the most strategically important growth markets through 2035.

India

India is becoming increasingly important because of its pharmaceutical manufacturing base, contract research activity, biotechnology development, and expanding forensic infrastructure.

Public investment in forensic capabilities is a major demand catalyst. Modernization of laboratories can increase demand for analytical instruments capable of identifying narcotics, controlled substances, metabolites, and other compounds.

Pharmaceutical R&D and contract research also create opportunities for advanced analytical systems.

India’s opportunity is particularly attractive because several demand sources are developing simultaneously. However, purchasing decisions can remain price-sensitive, making serviceability and operating cost important competitive factors.

Adoption outlook: High-growth market. Forensic modernization, pharmaceutical R&D, CRO activity, and laboratory expansion should support adoption.

Japan

Japan has a mature analytical laboratory ecosystem supported by pharmaceutical research, healthcare infrastructure, and sophisticated manufacturing capabilities.

Customers generally place strong emphasis on precision, reliability, reproducibility, and long-term technical support.

Unlike developing markets, growth is less dependent on new laboratory construction. Technology replacement, automation, analytical upgrades, and productivity improvements should account for a larger share of future demand.

Adoption outlook: Very high installed maturity with moderate growth potential.

South Korea

South Korea combines advanced technology infrastructure with a growing pharmaceutical and biotechnology sector.

Its biopharmaceutical industry is creating demand for modern analytical capabilities, while advanced manufacturing infrastructure supports adoption of automated laboratory systems.

The country is smaller than China or Japan in absolute market size but can offer attractive opportunities for suppliers focused on sophisticated laboratories.

Adoption outlook: High adoption with above-average strategic potential.

Middle East

The Middle East represents a selective opportunity rather than a uniform regional market.

Saudi Arabia and the United Arab Emirates are particularly relevant because of healthcare modernization, investment in laboratory infrastructure, pharmaceutical development, and public-sector testing capabilities.

Large centralized laboratories and government facilities are likely to account for a significant portion of demand. High-end analytical systems can benefit from investment in specialized forensic and healthcare infrastructure.

Adoption outlook: Developing to high in major investment centers, with demand concentrated in selected countries and institutions.

Country/Region	Infrastructure Maturity	Regulatory Environment	Funding/Investment Profile	2035 Growth Potential
United States	Very High	Very High	Very High	Moderate
Europe	High	Very High	High	Moderate
China	High and expanding	High	High	High
India	Developing and expanding	Increasing	Increasing	High
Japan	Very High	Very High	High	Moderate
South Korea	High	High	High	High
Middle East	Developing	Increasing	Increasing in major markets	Moderate–High

From an investment perspective, China and India offer the strongest combination of expanding laboratory capacity and long-term demand creation.

The United States, Europe, and Japan remain critical revenue centers because of their large installed bases and high-value analytical requirements. South Korea is strategically attractive because of its advanced biotechnology ecosystem, while the Middle East provides targeted opportunities linked to healthcare and forensic infrastructure.

Expert view: “Emerging markets have an unusual advantage: newly built laboratories can adopt automated and digitally connected workflows without carrying the same level of legacy infrastructure found in mature markets.”

Recent Developments + Opportunities & Restraints

Recent Developments

March 2025 — Point-of-need drug identification gains attention

Development work around portable, high-resolution analytical technologies is moving drug identification closer to the point of testing. Such systems could eventually allow selected drug-screening activities to be performed outside conventional centralized laboratories.

The trend is commercially relevant because faster preliminary identification can reduce the pressure on centralized facilities and shorten response times.

June 2025 — Drug-checking workflows move toward deeper laboratory analysis

New analytical approaches are improving the ability to recover and analyze drug material from used screening-test materials. This creates a potential bridge between rapid field screening and detailed laboratory confirmation.

The development highlights a broader movement toward combining simple screening methods with sophisticated downstream analytical testing.

May 2025 — Broader multi-drug screening methods emerge

Advanced analytical workflows are increasingly capable of screening hundreds of drugs and metabolites in a single analytical process.

This represents an important shift from narrow, predefined panels toward broader screening strategies. It can be particularly useful when laboratories need to identify unexpected compounds or emerging substances.

March 2025 — Forensic laboratory infrastructure expands in India

India continued expanding its forensic laboratory infrastructure, including investments in new and upgraded facilities.

The development has direct relevance to analytical testing demand because modern forensic laboratories require advanced systems for narcotics, toxicology, controlled-substance, and related examinations.

Opportunities & Business Insights

1. Emerging-market laboratory modernization

India, China, South Korea, and selected Middle Eastern markets offer opportunities as laboratories expand their analytical capabilities.

New facilities can be designed around automated workflows from the outset. This may allow suppliers to introduce integrated systems rather than selling individual instruments.

2. AI-assisted analysis and automation

AI-supported interpretation, automated sample preparation, workflow scheduling, and intelligent data review can improve productivity.

The strongest opportunity is likely to be in laboratories handling large datasets and high sample volumes. Software that helps analysts prioritize unusual findings can reduce review time while keeping human oversight in place.

3. Productivity-focused solutions

Laboratories increasingly need to process more samples without expanding staffing proportionally.

This creates opportunities for vendors offering automated preparation, higher-throughput instruments, integrated reporting, and remote instrument monitoring.

Key Restraints

High capital expenditure remains a barrier for smaller laboratories. Advanced analytical systems also require trained personnel, method validation, maintenance, and reliable technical support.

Data complexity is another constraint. High-resolution systems can generate large volumes of analytical information, increasing the need for effective software and skilled interpretation.

Regulatory requirements can also slow adoption of newer technologies. A laboratory may recognize the productivity benefits of a new system but still need extensive validation before incorporating it into a regulated workflow.

Expert view: “The commercial winner will not necessarily be the supplier with the most powerful instrument. It will often be the supplier that delivers the clearest improvement in laboratory productivity without creating additional operational complexity.”